Urgent needs to accelerate the race for COVID-19 therapeutics

Carolina Batista; Shmuel Shoham; Onder Ergonul; Peter Hotez; Maria Elena Bottazzi; J. Peter Figueroa; Sarah Gilbert; Mayda Gursel; Mazen Hassanain; Gagandeep Kang; David Kaslow; Jerome H. Kim; Bhavna Lall; Heidi Larson; Denise Naniche; Timothy Sheahan; Annelies Wilder-Smith; Samba O. Sow; Prashant Yadav; Nathalie Strub-Wourgaft

doi:10.1016/j.eclinm.2021.100911

Urgent needs to accelerate the race for COVID-19 therapeutics

Carolina Batista, Shmuel Shoham, Onder Ergonul, Peter Hotez, Maria Elena Bottazzi, J. Peter Figueroa, Sarah Gilbert, Mayda Gursel, Mazen Hassanain, Gagandeep Kang, David Kaslow, Jerome H. Kim, Bhavna Lall, Heidi Larson, Denise Naniche, Timothy Sheahan, Annelies Wilder-Smith, Samba O. Sow, Prashant Yadav, Nathalie Strub-Wourgaft

School of Medicine

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Article number	100911
Journal	EClinicalMedicine
Volume	36
DOIs	https://doi.org/10.1016/j.eclinm.2021.100911
State	Published - Jun 2021

ASJC Scopus subject areas

General Medicine

Access to Document

10.1016/j.eclinm.2021.100911

Cite this

Batista, C., Shoham, S., Ergonul, O., Hotez, P., Bottazzi, M. E., Figueroa, J. P., Gilbert, S., Gursel, M., Hassanain, M., Kang, G., Kaslow, D., Kim, J. H., Lall, B., Larson, H., Naniche, D., Sheahan, T., Wilder-Smith, A., Sow, S. O., Yadav, P., & Strub-Wourgaft, N. (2021). Urgent needs to accelerate the race for COVID-19 therapeutics. EClinicalMedicine, 36, Article 100911. https://doi.org/10.1016/j.eclinm.2021.100911

Batista, C, Shoham, S, Ergonul, O, Hotez, P, Bottazzi, ME, Figueroa, JP, Gilbert, S, Gursel, M, Hassanain, M, Kang, G, Kaslow, D, Kim, JH, Lall, B, Larson, H, Naniche, D, Sheahan, T, Wilder-Smith, A, Sow, SO, Yadav, P & Strub-Wourgaft, N 2021, 'Urgent needs to accelerate the race for COVID-19 therapeutics', EClinicalMedicine, vol. 36, 100911. https://doi.org/10.1016/j.eclinm.2021.100911

@article{412486546c3e48489e24e431389a3745,

title = "Urgent needs to accelerate the race for COVID-19 therapeutics",

author = "Carolina Batista and Shmuel Shoham and Onder Ergonul and Peter Hotez and Bottazzi, {Maria Elena} and Figueroa, {J. Peter} and Sarah Gilbert and Mayda Gursel and Mazen Hassanain and Gagandeep Kang and David Kaslow and Kim, {Jerome H.} and Bhavna Lall and Heidi Larson and Denise Naniche and Timothy Sheahan and Annelies Wilder-Smith and Sow, {Samba O.} and Prashant Yadav and Nathalie Strub-Wourgaft",

note = "Funding Information: MEB and PH are developers of a COVID-19 vaccine construct, which was licensed by Baylor College of Medicine to Biological E Ltd., a commercial vaccine manufacturer for scale up, production, testing and licensure. MG participates in one of eight SARS-CoV-2 vaccine development projects supported by The Scientific and Technological Research Council of Turkey (T{\"U}BİTAK) since March 2020. SG is cofounder of Vaccitech and has a patent on ChAdOx1 nCoV-19 licensed to AstraZeneca. MH is Founder and Managing Director of SaudiVax. JPF and GK are members of the WHO SAGE Working Group on COVID-19 vaccines. GK is independent director of Hilleman Laboratories Private Limited and Vice Chair of the Board, Coalition of Epidemic Preparedness Innovations (CEPI). DK reports grants from Bill and Melinda Gates Foundation (BMGF) and grants from CEPI. JHK reports personal fees from SK biosciences. HL reports grants and honoraria from GlaxoSmithKline for training talks and from Merck as a member of the Merck Vaccine Confidence Advisory Board, outside the submitted work. TS reports grants from National Institute of Allergy and Infectious Disease and Fast Grants and research contracts from GlaxoSmithKline, and ViiV Healthcare. SS reports grants from Ansun BioPharma, Astellas Pharma, Cidara Therapeutics, F2G, Merck, T2 Biosystems, Shire Pharmaceuticals, Shionogi, and Gilead Sciences, outside the submitted work; and personal fees from Amplyx Pharmaceuticals, Acidophil, Janssen Pharmaceuticals, Reviral, Intermountain Healthcare, Karyopharm Therapeutics, Immunome, and Celltrion, outside the submitted work. All other authors declare no conflict of interests. The authors views and opinions in the Commentary do not necessarily represent the views, decisions, or policies of the institutions, universities, or health systems with which they are affiliated. ",

year = "2021",

month = jun,

doi = "10.1016/j.eclinm.2021.100911",

language = "English (US)",

volume = "36",

journal = "EClinicalMedicine",

issn = "2589-5370",

publisher = "Lancet Publishing Group",

}

TY - JOUR

T1 - Urgent needs to accelerate the race for COVID-19 therapeutics

AU - Batista, Carolina

AU - Shoham, Shmuel

AU - Ergonul, Onder

AU - Hotez, Peter

AU - Bottazzi, Maria Elena

AU - Figueroa, J. Peter

AU - Gilbert, Sarah

AU - Gursel, Mayda

AU - Hassanain, Mazen

AU - Kang, Gagandeep

AU - Kaslow, David

AU - Kim, Jerome H.

AU - Lall, Bhavna

AU - Larson, Heidi

AU - Naniche, Denise

AU - Sheahan, Timothy

AU - Wilder-Smith, Annelies

AU - Sow, Samba O.

AU - Yadav, Prashant

AU - Strub-Wourgaft, Nathalie

N1 - Funding Information: MEB and PH are developers of a COVID-19 vaccine construct, which was licensed by Baylor College of Medicine to Biological E Ltd., a commercial vaccine manufacturer for scale up, production, testing and licensure. MG participates in one of eight SARS-CoV-2 vaccine development projects supported by The Scientific and Technological Research Council of Turkey (TÜBİTAK) since March 2020. SG is cofounder of Vaccitech and has a patent on ChAdOx1 nCoV-19 licensed to AstraZeneca. MH is Founder and Managing Director of SaudiVax. JPF and GK are members of the WHO SAGE Working Group on COVID-19 vaccines. GK is independent director of Hilleman Laboratories Private Limited and Vice Chair of the Board, Coalition of Epidemic Preparedness Innovations (CEPI). DK reports grants from Bill and Melinda Gates Foundation (BMGF) and grants from CEPI. JHK reports personal fees from SK biosciences. HL reports grants and honoraria from GlaxoSmithKline for training talks and from Merck as a member of the Merck Vaccine Confidence Advisory Board, outside the submitted work. TS reports grants from National Institute of Allergy and Infectious Disease and Fast Grants and research contracts from GlaxoSmithKline, and ViiV Healthcare. SS reports grants from Ansun BioPharma, Astellas Pharma, Cidara Therapeutics, F2G, Merck, T2 Biosystems, Shire Pharmaceuticals, Shionogi, and Gilead Sciences, outside the submitted work; and personal fees from Amplyx Pharmaceuticals, Acidophil, Janssen Pharmaceuticals, Reviral, Intermountain Healthcare, Karyopharm Therapeutics, Immunome, and Celltrion, outside the submitted work. All other authors declare no conflict of interests. The authors views and opinions in the Commentary do not necessarily represent the views, decisions, or policies of the institutions, universities, or health systems with which they are affiliated.

PY - 2021/6

Y1 - 2021/6

UR - http://www.scopus.com/inward/record.url?scp=85110434792&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85110434792&partnerID=8YFLogxK

U2 - 10.1016/j.eclinm.2021.100911

DO - 10.1016/j.eclinm.2021.100911

M3 - Comment/debate

C2 - 34036254

AN - SCOPUS:85110434792

SN - 2589-5370

VL - 36

JO - EClinicalMedicine

JF - EClinicalMedicine

M1 - 100911

ER -

Urgent needs to accelerate the race for COVID-19 therapeutics

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this